|
Mondorf, W; Klinge, J; Luban, N L et al. (2001) Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia 7:13-9
|
|
Klinge, J; Auerswald, G; Budde, U et al. (2001) Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia 7:26-32
|
|
Barrow, R T; Healey, J F; Gailani, D et al. (2000) Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 95:564-8
|
|
Fay, P J; Scandella, D (1999) Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 274:29826-30
|
|
Laub, R; Di Giambattista, M; Fondu, P et al. (1999) Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb Haemost 81:39-44
|
|
Sawamoto, Y; Prescott, R; Zhong, D et al. (1998) Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 79:62-8
|
|
Saenko, E L; Scandella, D; Yakhyaev, A V et al. (1998) Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem 273:27918-26
|
|
Saenko, E L; Scandella, D (1997) The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 272:18007-14
|
|
Thompson, A R; Murphy, M E; Liu, M et al. (1997) Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood 90:1902-10
|
